{
    "Trade/Device Name(s)": [
        "ROMA\u2122 (HE4 EIA + ARCHITECT CA 125 II\u2122)",
        "ROMA (Risk of Ovarian Malignancy Algorithm) using HE4 EIA and ARCHITECT CA 125 II"
    ],
    "Submitter Information": "Fujirebio Diagnostics, Inc.",
    "510(k) Number": "K103358",
    "Predicate Device Reference 510(k) Number(s)": [
        "K081754"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "ONX"
    ],
    "Summary Letter Date": "August 29, 2011",
    "Summary Letter Received Date": "August 30, 2011",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.6050"
    ],
    "Regulation Name(s)": [
        "Ovarian adnexal mass assessment score test system"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "HE4",
        "CA 125"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ARCHITECT System"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunometric assay (EIA)",
        "Chemiluminescent Microparticle Immunoassay (CMIA)",
        "Software algorithm"
    ],
    "Methodologies": [
        "Immunoassay",
        "Algorithmic risk score calculation"
    ],
    "Submission Type(s)": [
        "Test",
        "Software",
        "Reagent",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for ROMA serum cancer risk algorithm using HE4 EIA and ARCHITECT CA 125 II to stratify ovarian adnexal mass surgical candidates by malignancy likelihood",
    "Indications for Use Summary": "Aids in assessing if premenopausal or postmenopausal women (age 18+, ovarian adnexal mass present and surgery planned) are at high or low likelihood of malignancy on surgery; to be interpreted in conjunction with clinical and radiological assessment; not for screening or stand-alone diagnosis",
    "fda_folder": "Obstetrics"
}